RxDoctor Payments Data

Fernando de la Serna, MD

Interventional Cardiology · Morganton, NCNPI 1093923187

Payments from drug & device makers

$5,390in general payments, 2019–2025

Across 171 payments — averaging $31.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Novartis$438
  • Merck$249
  • E.r. Squibb & Sons, L.L.C.$227
  • Johnson & Johnson$219
  • Pfizer$202
  • plus $768 from 16 others

What the payments were for

  • Travel & lodging$1,46827%
  • Food & beverage$3,77170%
  • Education$1503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,390 in reported general payments places this provider in the 35th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$154,489
Medicare patients
1,323
Services billed
3,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$262,315
JardianceEmpagliflozin326$223,645
EntrestoSacubitril/Valsartan163$136,111
XareltoRivaroxaban97$84,848
Repatha SureclickEvolocumab86$72,685
BrilintaTicagrelor49$24,859
VascepaIcosapent Ethyl63$24,784
FarxigaDapagliflozin Propanediol16$13,947
Praluent PenAlirocumab14$12,298
NexletolBempedoic Acid28$11,276
VerquvoVericiguat12$7,835
Repatha SyringeEvolocumab12$6,527
Icosapent Ethyl15$4,706
Metoprolol Succinate372$4,125
Ranolazine ErRanolazine64$3,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$262,315349 claims
Boehringer IngelheimJardiance$159$223,645326 claims
NovartisEntresto$438$136,111163 claims
Johnson & JohnsonXarelto$219$84,84897 claims
AstraZenecaBrilinta, Farxiga$177$38,80765 claims
MerckVerquvo$249$7,83512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Morganton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →